-
1.发明公开公开(公告)号：US20240344020A1
公开(公告)日：2024-10-17
申请号：US18577457
申请日：2021-07-28
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Tao HUANG , Cheng CHEN
CPC classification number: C12N5/0018 , C12N5/0693 , C12N2501/105 , C12N2501/117 , C12N2501/12 , C12N2501/2306 , C12N2501/999 , C12N2503/02
Abstract: A primary cell culture medium for culturing primary lung cancer epithelial cells, containing an MST1/2 kinase inhibitor, a ROCK inhibitor, fibroblast growth factor 7, at least one additive of B27 additive and N2 additive, hepatocyte growth factor, insulin-like growth factor 1, interleukin 6, and a TGFβ type I receptor inhibitor. The invention also relates to a culture method using the primary cell culture medium and its application in the efficacy evaluating and screening of drugs. In the culture method, the primary cell culture medium is used to culture primary cells in a culture vessel coated with an extracellular matrix gel, to make the primary cells expend rapidly. A cell model obtained using the primary cell culture medium and the primary cell culture method can be used for the efficacy evaluating and screening of drugs.
-
2.发明申请公开(公告)号：US20240392251A1
公开(公告)日：2024-11-28
申请号：US18692569
申请日：2021-10-26
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Cheng CHEN , Tao HUANG
IPC: C12N5/09
Abstract: A primary cell culture medium for culturing primary lung cancer epithelial cells, a culture method using the primary cell culture medium, and an application thereof in drug efficacy evaluation and screening. The culture medium contains an MST1/2 kinase inhibitor, a ROCK kinase inhibitor, a fibroblast growth factor, at least one additive selected from a B27 additive and an N2 additive, an epidermal growth factor, transferrin, gastrin, and a TGFβ type I receptor inhibitor.
-
3.发明公开公开(公告)号：US20230235283A1
公开(公告)日：2023-07-27
申请号：US17918971
申请日：2020-04-23
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Wenchao WANG , Cheng CHEN , Tao REN , Li WANG
CPC classification number: C12N5/0625 , C12N5/0693 , C12N2501/11 , C12N2500/25 , C12N2501/727 , C12N2501/12 , C12N2501/15 , C12N2503/02
Abstract: Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.
-
4.发明申请公开(公告)号：US20230091960A1
公开(公告)日：2023-03-23
申请号：US17798640
申请日：2020-02-26
Applicant: PRECEDO PHARMACEUTICALS CO., LTD
Inventor： Qingsong LIU , Jie HU , Cheng CHEN , Wenchao WANG , Li WANG
Abstract: Provided are a culture medium and cultivation method of rapidly expanding primary cells of esophageal squamous carcinoma in vitro, and the use thereof in screening drugs. The culture medium comprises an initial culture medium selected from DMEM/F12, DMEM, F12, or RPMI-1640, a Rho protease inhibitor, an antibiotic, insulin, an N2 additive, insulin-like growth factor 1, a non-essential amino acid, and optionally, hydrocortisone, optionally, glutamine, and optionally, bovine pituitary extract.
-
-
-
Search Results
4
records
(took 0.025 seconds)
